RESPIVERT LIMITED

Patent Owner

Watch Compare Add to Portfolio

Stats

Details

Patent Activity in the Last 10 Years

Technologies

Intl Class Technology Matters Rank in Class
 
  
 
A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 50205
 
  
 
C07D HETEROCYCLIC COMPOUNDS 42120
 
  
 
C07F ACYCLIC, CARBOCYCLIC, OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM, OR TELLURIUM 664
 
  
 
C07C ACYCLIC OR CARBOCYCLIC COMPOUNDS 5133
 
  
 
A01N PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF 491
 
  
 
C07H SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 396
 
  
 
C12N MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF 1166
 
  
 
G01N INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 1205

Top Patents (by citation)

Upgrade to the Professional Level to View Top Patents for this Owner. Learn More

Recent Publications

Publication # Title Filing Date Pub Date Intl Class
2018/0000,830 INHIBITORS OF HEMOPOIETIC CELL KINASE (P-59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTIONSep 15, 17Jan 04, 18[A61K, C12N, G01N]
2017/0334,919 2-((4-AMINO-3-(3-FLUORO-5-HYDROXYPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1 -YL)METHYL)-3-(2-(TRIFLUORO-MET HYL)BENZYL)QUINAZOLIN-4(3H)-ONE DERIVATIVES AND THEIR USE AS PHOSPHOINOSITIDE 3-KINASE INHIBITORSJul 27, 17Nov 23, 17[A61K, C07D]
2017/0239,256 CRYSTALLINE Pl3 KINASE INHIBITORSMay 08, 17Aug 24, 17[A61K]
2017/0209,445 KINASE INHIBITORSOct 01, 15Jul 27, 17[A61K]
2016/0318,909 KINASE INHIBITORSJul 12, 16Nov 03, 16[A61K, C07F, C07D]
2016/0009,695 1-PYRAZOLYL-3- (4- ((2 -ANILINOPYRIMIDIN- 4 - YL) OXY) NAPTHTHALEN- I - YL) UREAS AS P38 MAPKINASE INHIBITORSJul 10, 15Jan 14, 16[A61K, C07D]
2015/0099,768 NOVEL PHARMACEUTICAL FORMULATIONSMar 13, 13Apr 09, 15[A61K]

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
9890185 Urea derivatives useful as kinase inhibitorsDec 19, 14Feb 13, 18[A61K, C07F, C07D]
9884845 Pyrazolyl-ureas as kinase inhibitorsFeb 13, 15Feb 06, 18[A61K, C07D]
9850231 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-I-yl) ureas as P38 mapkinase inhibitorsJul 10, 15Dec 26, 17[A61K, C07D]
9850233 Kinase inhibitorsJul 12, 16Dec 26, 17[A61K, C07F, C07D]
9834560 CompoundsMar 31, 16Dec 05, 17[A61K, C07D]
9822076 Kinase inhibitorOct 12, 16Nov 21, 17[A61K, C07H, C07F, C07D]
9796742 Kinase inhibitorsAug 04, 16Oct 24, 17[A61K, C07F, C07D]
9790174 Kinase inhibitorsSep 09, 16Oct 17, 17[A61K, C07D, C07C]
9790209 Kinase inhibitorsAug 01, 16Oct 17, 17[A61K, C07F, C07D, C07C]
9783556 Kinase inhibitorsAug 28, 13Oct 10, 17[A61K, C07F]

View all patents..

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
2016/0045,482 UREIDO-PYRAZOLE DERIVATIVESAbandonedOct 27, 15Feb 18, 16[A61K, C12Q]
2016/0045,512 Inhibitors of Hemopoietic Cell Kinase (P59-HCK) and Their Use in the Treatment of Influenza InfectionAbandonedOct 14, 15Feb 18, 16[A61K, C12N, G01N]
2016/0016,934 KINASE INHIBITORSAbandonedMar 13, 14Jan 21, 16[A61K, C07D]
2015/0225,373 KINASE INHIBITORSAbandonedAug 28, 13Aug 13, 15[A61K, C07F, C07D, C07C]
2015/0210,722 KINASE INHIBITORSAbandonedAug 28, 13Jul 30, 15[A61K, C07F, C07D]
2014/0057,915 KINASE INHIBITORSAbandonedAug 16, 13Feb 27, 14[A61K, C07D]
2013/0123,260 MethodsAbandonedJun 17, 11May 16, 13[A61K, C07D]
2013/0029,990 PYRAZOLE P38 MAP KINASE INHIBITORSAbandonedApr 01, 11Jan 31, 13[A61K, C07D, A61P]
2012/0244,120 INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTIONAbandonedDec 10, 10Sep 27, 12[A61K, C07H, C12Q, A61P]

Top Inventors for This Owner

Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!

We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.